Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells

Cancer Science

Volumn 105, Issue 5, 2014, Pages 560-567

  Otsubo, Tsuguteru ^a   Hida, Yasuhiro ^b   Ohga, Noritaka ^c   Sato, Hideshi ^a   Kai, Toshihiro ^a   Matsuki, Yasushi ^a   Takasu, Hideo ^a   Akiyama, Kosuke ^c   Maishi, Nako ^c   Kawamoto, Taisuke ^c   Shinohara, Nobuo ^b   Nonomura, Katsuya ^b   Hida, Kyoko ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antiangiogenic therapy; Normal endothelial cell; Tumor angiogenesis; Tumor endothelial cell; Tumor endothelial cell marker

Indexed keywords

CD11B ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; SMALL INTERFERING RNA; TUMOR MARKER; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR 1; VASCULOTROPIN; VASCULOTROPIN C;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; DNA MICROARRAY; DRUG IDENTIFICATION; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MELANOMA; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR ENDOTHELIAL CELL; UPREGULATION; VASCULAR TUMOR;

ANTIANGIOGENIC THERAPY; NORMAL ENDOTHELIAL CELL; TUMOR ANGIOGENESIS; TUMOR ENDOTHELIAL CELL; TUMOR ENDOTHELIAL CELL MARKER;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84899907702     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12394     Document Type: Article

References (51)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
3. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
4. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4 (Suppl. 2): S62-8.
5. Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets 2011; 11: 624-53.
6. Young RJ, Reed MWR. Anti-angiogenic therapy: concept to clinic. Microcirculation 2012; 19: 115-25.
7. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-85.
8. Ratner M. Genentech discloses safety concerns over avastin. Nat Biotechnol 2004; 22: 1004-198.
9. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007; 14: 1860-9.
10. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-95.
11. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
12. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
13. Folkman J. Fundamental concepts of the angiogenesis process. Curr Mol Med 2003; 3: 643-51.
14. Chung AS, Lee J, Ferrara N. Targeting the tumor vascalature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-14.
15. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713-25.
16. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-11.
17. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002; 62: 5381-5.
18. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
19. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61: 6649-55.
20. Nanda A. St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004; 16: 44-9.
21. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-54.
22. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25: 852-61.
23. Lu C, Bonome T, Li Y et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67: 1757-68.
24. van Beijnum JR, Dings RP, van der Linden E et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-48.
25. Auerbach R, Akhtar N, Lewis RL, Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000; 19: 167-72.
26. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005; 65: 2507-10.
27. Hida K, Hida Y, Amin DN et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249-55.
28. Matsuda K, Ohga N, Hida Y et al. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 2010; 394: 947-54.
29. Ohga N, Hida K, Hida Y et al. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci 2009; 100: 1963-70.
30. Akiyama K, Ohga N, Hida Y et al. Tumor endothelial cells acquire drug resistance by MDR1 upregulation via VEGF signaling in tumor microenvironment. Am J Pathol 2012; 180: 1283-93.
31. Ohga N, Ishikawa S, Maishi N et al. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from highly metastatic and low metastatic tumors. Am J Pathol 2012; 180: 1294-307.
32. Yamamoto K, Ohga N, Hida Y et al. Biglycan is a specific marker and an autocrine angiogenic factor of tumor endothelial cells. Br J Cancer 2012; 106: 1214-23.
33. Maishi N, Ohga N, Hida Y et al. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol Int 2012; 62: 309-17.
34. Osawa T, Ohga N, Hida Y et al. Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. Cancer Sci 2012; 103: 1038-44.
35. Kozlowski JM, Hart IR, Fidler IJ, Hanna N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 1984; 72: 913-7.
36. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70.
37. Sobin LH, Gospodarowicz MK, Wittekind C. The TNM Classification of Malignant Tumours. 7th edn. Hoboken, NJ: Union for International Cancer Control (UICC), 2009.
38. Mavrakis KJ, McKinlay KJ, Jones P, Sablitzky F. DEF6, a novel PH-DH-like domain protein, is an upstream activator of the Rho GTPases Rac1, Cdc42, and RhoA. Exp Cell Res 2004; 294: 335-44.
39. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-14.
40. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001; 11: 471-7.
41. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093-101.
42. Banyard J, Anand-Apte B, Symons M, Zetter BR. Motility and invasion are differentially modulated by Rho family GTPases. Oncogene 2000; 19: 580-91.
43. Zhang Z, Wang Q, Li P et al. Overexpression of the interferon regulatory factor 4-binding protein in human colorectal cancer and its clinical significance. Cancer Epidemiol 2009; 33: 130-6.
44. Li P, Zhang Z, Wang Q et al. The ectopic expression of IFN regulatory factor 4-binding protein is correlated with the malignant behavior of human breast cancer cells. Int Immunopharmacol 2009; 9: 1002-9.
45. Lurton J, Rose TM, Raghu G, Narayanan AS. Isolation of a gene product expressed by a subpopulation of human lung fibroblasts by differential display. Am J Respir Cell Mol Biol 1999; 20: 327-31.
46. Zuccolo J, Bau J, Childs SJ et al. Phylogenetic analysis of the MS4A and TMEM176 gene families. PLoS ONE 2010; 5: e9369.
47. Gottschling S, Jauch A, Kuner R et al. Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. Lung Cancer 2012; 75: 45-57.
48. Strelnikov V, Tanas A, Shkarupo V, Kuznetsova E, Gorban N, Zaletayev D. Non-microarray DNA differential methylation screening in breast cancer. Cancer Genet Cytogenet 2010; 203: 93.
49. Hodo Y, Hashimoto S, Honda M et al. Comprehensive gene expression analysis of 5′-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. Genomics 2010; 95: 217-23.
50. Ryu SH, Kim KH, Kim HB et al. Oncogenic Ras-mediated downregulation of Clast1/LR8 is involved in Ras-mediated neoplastic transformation and tumorigenesis in NIH3T3 cells. Cancer Sci 2010; 101: 1990-6.
51. Cuajungco MP, Podevina W, Valluri VK, Bui Q, Nguyen VH, Taylor K. Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology. Acta Histochem 2012; 114: 705-12.